Entropy Neurodynamics requests an ASX trading halt ahead of a significant U.S. Phase 2 clinical trial update with Robin Carhart-Harris

Entropy Neurodynamics, the ASX-listed biotechnology company operating under Tryptamine Therapeutics, has requested a trading halt in its ordinary shares from the start of trading on 24 August 2026. The halt is expected to continue until 26 August or until the company releases a pending announcement, which concerns a U.S. Phase 2 clinical trial conducted with Professor Robin Carhart-Harris. The ASX confirmed that the securities will remain halted unless it determines otherwise. The company said it was unaware of any reason the request should not be granted, indicating an effort to manage information flow and preserve market integrity before potentially material clinical and strategic news is disclosed. The update may affect valuation and investor expectations, although the supplied material does not report the trial results or identify the therapy being studied.